| http://www.w3.org/ns/prov#value | - se mutations are common in several incurable cancers,??? says Jeffrey Engelman, MD, PhD, of Mass General Cancer Center, one of the report???s co-lead authors. ???Cancers with K-Ras mutations have been resistant to all targeted therapies to date, and it is exciting to learn that a combination of PI3K and MEK inhibitors, two families of drugs currently in clinical development, may be highly effectiv
|
